BILLERICA, Mass.–Quanterix Corporation reported third-quarter 2026 revenue of $35 million, representing a 6.3% increase from the previous quarter, as the life sciences technology company advanced commercial restructuring efforts and expanded its diagnostics business, particularly in blood-based testing for Alzheimer’s disease.
Revenue for the quarter ended September 30 declined approximately 13.1% from $40.2 million in the same period last year. However, the sequential improvement reflected stronger performance across the company’s research tools and diagnostics operations despite continued weakness in the broader market.
Quanterix reported a net loss of $21.6 million, an improvement of 35.6% compared with the prior-year period. Its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) showed a loss of $12.2 million.
The company’s gross margin under generally accepted accounting principles (GAAP) was 38.6%, down 90 basis points from a year earlier. Adjusted gross margin increased 150 basis points to 47.4%.
Quanterix ended the quarter with $80.7 million in cash, cash equivalents, marketable securities and restricted cash.
“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercial performance, including reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond,” said Everett Cunningham, President and CEO of Quanterix.
The company has been restructuring its commercial operations and strengthening its management team to support growth in research tools and clinical diagnostics.
As part of those efforts, Quanterix appointed Jim Gute as Chief Commercial Officer in August and Yuri Fesko, MD, as its first Chief Medical Officer in September. The appointments are intended to strengthen commercial execution, clinical development and regulatory operations.
A major focus of the company’s strategy is expanding access to blood-based biomarker testing for Alzheimer’s disease and other neurological disorders.
Quanterix recently announced expanded insurance coverage for qualifying blood-based biomarker tests in Florida. Beginning November 1, 2026, traditional Medicaid members and state employees became eligible for coverage of certain tests, including the company’s LucentAD Complete, when medical necessity requirements are satisfied.
The company also established commercial partnerships with Sherman Abrams Lab in New York and TruPath in Mississippi, expanding its network of clinical reference laboratories offering diagnostic testing services.
Internationally, Quanterix reported additional regulatory approvals in China for neurological biomarker testing using its HD-X and SR-X instruments and associated testing kits.
The company is working with Innovita Biological Technology Co., a Chinese diagnostics company, to broaden access to blood-based biomarker testing through its SIMOA technology platform.
SIMOA is an ultrasensitive protein detection technology designed to identify and measure biomarkers in blood and other biological fluids at concentrations that conventional testing methods may not detect.
Quanterix also expanded its SIMOA assay portfolio with additional testing options targeting biomarkers associated with Alzheimer’s disease and other neurodegenerative conditions.
Beyond blood-based diagnostics, the company continued developing its spatial biology business, which uses advanced tissue analysis technologies acquired through Akoya Biosciences.
During the European Society for Spatial Biology meeting in September, Quanterix introduced three new spatial biology products.
The PhenoCode 2.0 Molecular Barcoding Kit entered full commercial release, allowing researchers to label antibodies for applications in immuno-oncology, neuroscience and other research areas.
Two additional products, the TIME panel and a high-plex antibody-drug conjugate (ADC) panel, are expected to begin shipping in early 2027.
The TIME panel is designed to provide researchers with a more detailed understanding of the tumor immune microenvironment, while the ADC panel enables simultaneous analysis of drug target expression and immune characteristics within tissue samples.
Quanterix also announced that its Accelerator Laboratory is accepting requests for custom ADC panel development, expanding its services for biopharmaceutical companies and translational research organizations.
“We are confident about the benefits and differentiated positioning of our research tools and diagnostics businesses, especially with new commercial leadership focused on sustained growth. Our continued innovation in ultra-sensitive protein-detection in blood and high plex spatial analysis in tissue provides us with market advantages in targeted discovery and translational research. Lastly, we have now established a strong foundation for Quanterix in diagnostics, through strategic investments and partnerships, enabling us to focus on achieving key milestones in Alzheimer’s disease testing, with our single-site Alzheimer’s disease five biomarker blood test,” Cunningham said.
Looking ahead, Quanterix narrowed its full-year 2026 revenue guidance to between $142 million and $146 million.
The company maintained its expectation for adjusted gross margins of 48% to 50% and projected that it would finish 2026 with approximately $70 million in cash and no debt.
Quanterix said its commercial restructuring, expanded diagnostics partnerships and continued investment in biomarker technologies are expected to support future growth as it works to increase adoption of its research and clinical testing platforms.
